Literature DB >> 12149195

Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors.

David G Oscier1, Anne C Gardiner, Sarah J Mould, Sharron Glide, Zadie A Davis, Rachel E Ibbotson, Martin M Corcoran, Robert M Chapman, Peter W Thomas, J Adrian Copplestone, Jenny A Orchard, Terry J Hamblin.   

Abstract

This study evaluates the prognostic significance of genetic abnormalities (detected at or shortly after presentation), clinical stage, lymphocyte morphology, CD38 expression, and IGVH gene status in 205 patients with chronic lymphocytic leukemia (B-CLL). Deletion of chromosome 11q23, absence of a deletion of chromosome 13q14, atypical lymphocyte morphology, and more than 30% CD38 expression are significantly associated with the presence of unmutated IGVH genes. Advanced stage, male sex, atypical morphology, more than 30% CD38 expression, trisomy 12, deletion of chromosome 11q23, loss or mutation of the p53 gene, and unmutated IGVH genes are all poor prognostic factors in a univariate analysis. However, only 98% or more homology of IGVH genes to the germline sequence, loss or mutation of the p53 gene, and clinical stage retain prognostic significance in a multivariate analysis. The median survival of patients with mutated IGVH genes, unmutated IGVH genes, and loss or mutation of the p53 gene regardless of IGVH gene status is 310, 119, and 47 months, respectively. These data should facilitate the design of new trials for the management of patients presenting with advanced disease or poor prognosis early stage disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149195

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  94 in total

1.  Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia.

Authors:  O Moshynska; K Sankaran; A Saxena
Journal:  Mol Pathol       Date:  2003-08

2.  Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia.

Authors:  Thorsten Zenz; Daniel Mertens; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2010-09       Impact factor: 9.941

3.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Authors:  David Oscier; Rachel Wade; Zadie Davis; Alison Morilla; Giles Best; Sue Richards; Monica Else; Estella Matutes; Daniel Catovsky
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

4.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

5.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

6.  Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.

Authors:  Roberto Marasca; Rossana Maffei; Monica Morselli; Patrizia Zucchini; Ilaria Castelli; Silvia Martinelli; Marcella Fontana; Sara Ravanetti; Monica Curotti; Giovanna Leonardi; Katia Cagossi; Giovanni Partesotti; Giuseppe Torelli
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

Review 7.  Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Richard Rosenquist
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 8.  The dark side of activation-induced cytidine deaminase: relationship with leukemia and beyond.

Authors:  Kazuo Kinoshita; Taichiro Nonaka
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

9.  Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.

Authors:  Jennifer A Woyach; Nyla A Heerema; John Zhao; Andrew McFaddin; Amy Stark; Thomas S Lin; Leslie A Andritsos; Kristie A Blum; Joseph M Flynn; Jeffrey A Jones; John C Byrd
Journal:  Br J Haematol       Date:  2009-12-16       Impact factor: 6.998

10.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.